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Abstract 
Breast cancer (BrCa) remains the leading cause of cancer-related deaths in women 
worldwide (2). Current research suggests that the transcription factor RUNX1 functions as a 
regulator and potentially as a tumor suppressor in breast cancer progression (4). RUNX1 is the 
most dominant RUNX family member expressed in normal mammary epithelial cells (10) and it 
has been demonstrated that RUNX1 activity decreases as breast cancer aggression increases. 
Yet, the mechanism of this regulation remains unclear. The significance of this project is to 
further the in-depth investigation of the relationship between RUNX1 and differentially 
expressed genes that influence human breast cancer progression. This study addresses the 
hypothesis that RUNX1 controls a myriad of genes that play roles in the suppression of the 
breast cancer stem cell (BCSC) population, a subpopulation of cancer cells that are capable of 
self-renewal and demonstrate an ability to resist common chemotherapies and treatments. 
BCSCs are therefore the most dangerous and most essential to eradicate if the cancer is to be 
cured (11). To test this hypothesis, RUNX1 was downregulated in the MCF10A breast cancer cell 
line using both the inducible CRISPRi and the shRNA-mediated gene knockdown approaches. 
Fluorescence-activated cell sorting (FACS) and quantitative polymerase chain reaction (qPCR) 
confirmed successful knockdown of RUNX1 and further genetic and proteomic expression 
analyses of known breast cancer driver genes was performed to determine how RUNX1 
depletion exerts control over the progression of BrCa. It was found that RUNX1 may aid in 
maintaining the epithelial phenotype in BrCa while also suppressing the expression of key BrCa 
driver genes such as phosphatidylinositol-3-kinases (PI3K) PIK3CA and PIK3R1. Investigating the 
role of RUNX1 as a suppressor of the BCSC population adds a new level of knowledge to the 
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field of breast cancer research, and may allow development of a safer, more targeted, and 
more effective plan of action to eradicate one of the deadliest diseases that exists today.  
Introduction 
Cancer is an incredibly complex and diverse disease that has the potential to affect 
every cell, tissue and organ of the body. Cancers touch every area of the globe and do not 
distinguish among age, sex, race, or ethnicity. Yet, underlying all cancers are key cellular and 
molecular hallmarks that allow cancers to evolve into lethal neoplastic diseases we see every 
day, from acute myeloid leukemia to breast cancer.   
For decades, the cellular and molecular foundation of cancer cells has been explained as 
six hallmarks that contribute to the canonical cancer cell: a cell that displays an ability to rapidly 
grow, proliferate and divide, eventually becoming immortal and capable of invasion and 
metastasis. By sustaining proliferative signaling via an array of tyrosine kinase domains, 
paracrine or autocrine signaling, the cancer cell exhibits chronic proliferation that is largely out 
of control (5). This fundamental property of the cancer cell is further compounded by its ability 
to evade the regulatory suppression of growth. Contact inhibition is abolished and a net loss of 
the canonical growth suppressors that include retinoblastoma-associated protein (RB1) and 
TP53, a well-documented protein with anticancer activity via DNA damage response and cell 
cycle control, is often seen. In parallel to the cancer cell evading suppression of growth, the 
ability to resist cell death is also a characteristic of cancers. In a healthy cell, hyperproliferation 
often leads to increased DNA damage, which is sensed by the cell to either fix the DNA damage 
or induce apoptosis if the damage is too severe to be repaired. As these DNA damage sensors 
are lost, the apoptotic cascade fails, allowing the DNA damaged cell to continue 
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hyperproliferation (5). As these events transpire, the cell may soon reach a state of 
immortalization, in which repetitive divisions and growth do not result in cell senescence or 
crisis.  
In order for a cancer cell to sustain the proliferative state, nutrient and energy 
requirements must still be met. The cell requires oxygen, nutrients, and an outlet for waste 
products such as carbon dioxide. As the cancer cell continues to mutate and progress, the 
angiogenic switch, often seen in embryonic and prenatal development, is turned on via hypoxia 
and oncogene signaling (5). This supports neoplastic growth by continually sprouting new blood 
vessels for nutrient delivery and waste removal. In the most progressive state, the cancer will 
activate mechanisms that allow for invasion and metastasis. It is thought that the loss of cell to 
cell and cell to extracellular matrix adhesion molecules allows the cancer to spread throughout 
the body. It is at this stage where the epithelial to mesenchymal transition (EMT) has been 
observed, a regulatory pathway that allows the cell to invade, metastasize, and resist the 
normal apoptotic programs. Key transcriptional factors are at play during EMT, most notably 
Snail, Slug, Twist, and Zeb1/2, all of which function to cause a net loss in cellular E-cadherin, a 
key cellular adhesion molecule (12). This marks the process known as the invasion-metastasis 
cascade. Following local invasion, intravasation occurs allowing the cell to travel throughout the 
circulatory and lymphatic systems. The cell then leaves this mode of transit via extravasation to 
settle in a distant part of the body, ideally one that provides a rich microenvironment for the 
cell to colonize the area and eventually grow into a macroscopic tumor. Most often, this 
cascade results in the cancer cell colonizing a niche environment, an area of the body that is 
rich in nutrients necessary for cellular survival. As these events transpire in a successive 
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manner, the result is an invasive subpopulation of cancer that can be aggressive and often 
lethal. 
In just the last decade, tumors have been categorized as functioning and complex organs. 
No longer can a tumor be simply considered a collection of homogenous cells. Rather, a tumor is 
made up of a diverse array of heterogeneous cells, each type specialized in its own way and 
harboring unique mutations (5). These types may include, but are not limited to, local stem and 
progenitor cells, immune inflammatory cells, cancer cells, pericytes, endothelial cells, cancer-
associated fibroblasts, invasive cancer cells, and cancer stem cells (CSCs) (11). Each of these cell 
types performs a unique function within the tumor organ and the tumor microenvironment. 
Immune inflammatory cells, for example, demonstrate tumor-promoting as well as tumor-
suppressive subtypes (Figure 1).  
Figure 1: The Heterogenous Cells 
of the Tumor Microenvironment. 
A multitude of cell types constitute 
solid tumors that together enable 
tumor growth and progression 
(upper). The characteristics of the 
cells evolve as they progress from 
a primary tumor, to an invasive or 
metastatic state (lower) (5).  
Acquired from Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 
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Recently, CSCs have come to the forefront of cancer research, as these cells are able to 
propagate new tumors upon host inoculation. Additionally, CSCs characteristically display 
expression of markers that are also found on stem cells in the same tissue-of-origin. Similar to 
healthy stem cells, CSCs are capable of self-renewal and therefore pose a significant threat 
when coupled with the canonical trademarks of a cancer cell (11). One such threat is an 
increased resistance to some of the most widely used cancer therapies today, such as 
chemotherapy. Furthermore, when a subpopulation of the tumor is resistant to 
chemotherapeutics, the treatment behaves as a selective pressure on the cancer population, 
allowing only the resistant CSCs to survive and foster a stronger and potentially deadly patient 
relapse. Investigating CSCs is therefore critical to understand how cancer progresses and to 
develop cancer therapies that truly eradicate the genetically heterogeneous tumor. 
In mammals, three RUNX genes encode transcription factors that serve as master 
regulators of development. RUNX1, RUNX2, and RUNX3 each display unique expression 
patterns that are critical to certain tissues and organ systems (4). RUNX proteins operate as 
effectors of crucial developmental pathways, including transforming growth factor-b (TGF-b), 
WNT, Notch, and receptor tyrosine kinases (4). This has led the RUNX family to be an important 
area of interest in oncological and carcinogenesis research. RUNX1 is essential for normal 
hematopoiesis and is heavily involved in human leukemia, while RUNX2 is an important bone 
lineage factor involved in osteosarcoma. In metastatic breast and prostate cancers, RUNX2 is 
often overexpressed, pointing to a role in tumorigenesis and metastasis (4).  
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The RUNX1 gene is located on the long arm of chromosome 21 (21q22.12) and 
expression of RUNX1 is regulated by two promoters known as P1 (distal) and P2 (proximal) (8). 
Due to alternative splicing, the RUNX1 gene is capable of producing several isoforms that 
encode proteins with unique properties. Each RUNX family member contains a highly conserved 
DNA-binding domain known as the Runt domain (Figure 2). It is in this domain that the 
heterodimeric binding partner, core-binding factor-beta (CBFb), binds and displaces the 
inhibitory domain of RUNX. CBFb is therefore crucial to gene regulation of the developmental 
pathways of hematopoiesis and osteogenesis (13). Though CBFb does not directly bind DNA, it 
exerts control by allosterically enhancing DNA binding at certain enhancers and gene promoters 
(13). The Runt domain is also subject to frequent mutations which result in an overall loss in 
DNA-binding ability. Furthermore, the RUNX proteins are subject to post-translation 
modifications, allowing the transcription factors to fulfill their role as master regulators of 
development. These modifications include methylation, acetylation, phosphorylation and 
ubiquitylation, all of which facilitate the impressive list of activating and inhibitory 
Figure 2: Functional domains of RUNX proteins and their interacting proteins. RUNX proteins 
contain a highly conserved Runt domain at the N-terminus at which CBF𝛃 and DNA bind. The 
Runt domains exhibit 90% homology among all RUNX family members (8).   
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developmental control mechanisms exerted by RUNX1 (4). RUNX1 also associates with cyclin-
dependent kinases (CDKs), and its phosphorylation status determines the stability of the 
protein and the control of the cell transition from G1 to S phase and further proliferation (4).  
Due to the master regulator role of RUNX1 in developmental control, genomic 
dysregulation can lead to the onset of many types of cancer, especially those derived from 
hematopoietic cells. Similarly, RUNX1 aberrations resulting from specific chromosomal 
translocations and gene fusions lead to the onset of specific leukemia subtypes, such as the 
development of acute lymphoblastic leukemia (ALL) following t(12;21) and the resulting TEL-
AML1 fusion gene (4).  
As stated, the role of RUNX1 in hematopoiesis is well-known, but its function in 
epithelial cells is much less understood. RUNX proteins recognize a core genomic sequence (4) 
and recruit mediators of signaling pathways, chromatin remodelers, and chromatin organizing 
proteins to regulatory regions of target genes. These genes in turn coordinate the control of 
proliferation, growth and differentiation (8, 14, 15). Several reports have demonstrated a lower 
expression of RUNX1 across BrCa progression (3, 16, 17); RUNX1 expression decreases as the 
aggression of the breast cancer increases (4). Therefore, in breast cancer specifically, increased 
RUNX1 expression is a characteristic of good prognosis, indicating that RUNX1 acts as a tumor 
suppressor (3). RUNX factors are implicated in normal mammary stem cell maintenance (18-21) 
and mammary gland development (22-25). Additionally, both RUNX1 and its heterodimeric 
binding partner CBFb are prevalent among predicted driver mutations in BrCa (2, 26, 27). The 
majority of these mutations indicate a loss of function (28). Knockdown of RUNX1 facilitates 
estrogen-induced Wnt signaling (10), an epithelial to mesenchymal transition (3) and 
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morphological defects (29). Furthermore, RUNX1 contributes to p53-dependent DNA damage 
response, a key mechanism facilitated by the p53 tumor suppressor (3). There are conflicting 
reports whether RUNX1 acts as a tumor suppressor or an oncogene in BrCa; one explanation for 
this discrepancy may be due to the model that BrCa consists of a diverse group of subtypes 
(30). These BrCa subtypes have different cellular origins (luminal versus basal) and molecular 
alterations (e.g., hormonal status including ER, PR, and HER2) that result in malignancy. More 
work is required to determine the molecular mechanisms by which RUNX1 functions in BrCa. 
Our research group has demonstrated that RUNX1 is involved in a key biological 
process, the epithelial to mesenchymal transition (EMT) (3). During EMT, epithelial cadherin (E-
cadherin/CDH1) and tight cell-cell junctions are lost, allowing epithelial cells to transition to 
mesenchymal cells (31). Normally, EMT is a process crucial to development, most notably 
gastrulation and organ development during embryogenesis (12). However, EMT is also utilized 
by early stage tumors to form invasive malignancies in breast cancer (12). As a result of EMT, 
breast cancers display invasive properties that allow the cancer to metastasize and progress to 
a more aggressive state with a poorer prognosis. During progression, early stage cancer cells 
displaying the epithelial phenotype, a state that requires cell to cell contact and lacking 
mobility, transition to a mesenchymal phenotype. Mesenchymal cells lack a polarized 
cytoskeleton and therefore display a change in cellular morphology that is more spindle-
shaped, aiding in the cell’s ability to metastasize and survive with reduced cell to cell contact 
(Figure 3) (3).  
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Recent research demonstrates that RUNX1 maintains the normal epithelial phenotype 
and that RUNX1 expression is inversely related to the relative aggression of breast cancer (3). 
For instance, in the MCF10 breast cancer cell line progression series, RUNX1 RNA expression 
decreases as the cancer aggression progresses from normal-like MCF10A mammary epithelial 
cells through tumorigenic MCF10AT1 cells to the metastatic MCF10CA1a cells (Figure 4A) (3). 
Furthermore, by quantitatively analyzing expression of the cellular markers E-cadherin and 
vimentin through the MCF10 series, EMT has been shown to progress as RUNX1 expression 
decreases (Figure 4B). This is exemplified by a decrease of E-cadherin expression and an 
increase in expression of vimentin, an intermediate filament present in mesenchymal cells. This 
relationship between RUNX1 and EMT further supports the role of RUNX1 as a tumor 
suppressor in breast cancer.   
Moreover, upon shRNA-mediated knockdown of RUNX1 in MCF10A cells, E-cadherin 
exhibits a significant decrease in mRNA expression while both vimentin and N-cadherin, a 
known protein marker for cancer metastasis, display a significant increase in mRNA expression 
(Figure 5) (3).  
 
Figure 3: The Epithelial to Mesenchymal Transition contributes to the progression of cancer. 
As EMT progresses, cells lack cellular adhesion markers such as E-cadherin and express 
mesenchymal markers vimentin and N-cadherin. The mesenchymal phenotype contributes to 
cellular invasion and cancer metastasis (6).  
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4A 4B 
Figure 4: Expression profiles in the MCF10A Breast Cancer Cell Series. A: RUNX1 RNA 
expression by RT-qPCR of normal mammary-like MCF10A cells, MCF10A-derived 
tumorigenic MCF10AT1 cells, and metastatic MCF10CA1a cells demonstrates a reduction 
in RUNX1 as the series progresses. B: Protein expression by western blot analysis of the 
MCF10A series demonstrates a reduction in RUNX1 and E-cadherin and an increase in 
Vimentin as the series progresses to metastasis (3).    
5A 5B 
5C 5D 
Figure 5: RUNX1 Depletion in MCF10A Cells Advances the Mesenchymal-like Phenotype. 
Western blot analyses of cell lysates show a decrease in RUNX1 expression (A) upon shRNA-
mediated knockdown of RUNX1 relative to the non-silencing (NS) shRNA construct. A 
decrease in E-cadherin (B) is observed upon RUNX1 knockdown as well as an increase in 
the mesenchymal genes N-cadherin (C) and Vimentin (D) (3).  
RUNX1 mRNA  E-cadherin mRNA  
N-cadherin mRNA  Vimentin mRNA  
RUNX1  
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Recent studies have shown that overexpression of RUNX1 is able to rescue and reverse 
the EMT phenotype after TGFb-induced EMT. Upon overexpression of RUNX1, E-cadherin 
mRNA expression increased while vimentin mRNA expression decreased. This rescue study 
therefore established the significant role of RUNX1 in preventing EMT (3). With the evidence of 
EMT progression as a result of RUNX1 knockdown, RUNX1 can be considered a tumor 
suppressor gene in mammary epithelial cells.  
 In all cancers, genomic mutations may be classified as driver or passenger mutations. A 
driver mutation is one that promotes the progression of the cancer and is causally implicated in 
doing so. Driver mutations confer growth advantages on the cancer and are therefore positively 
selected for in the tumor microenvironment. Conversely, mutations known as passenger 
mutations are not selected for, as they do not directly contribute to cancer development. 
Passenger mutations commonly occur during cellular division and do not carry severe 
functional consequences. Therefore, the more developed cancer will harbor a number of driver 
mutations along with a variety of passenger mutations that were carried throughout the 
development of the cancer (36). In 2016, Serena Nik-Zainal and colleagues analyzed whole 
genome sequences of 560 patient-derived breast cancers using massively-parallel sequencing 
to gain a better understanding of the genetic mutations driving BrCa, clonal advantages, and 
the processes generating these somatic mutations (1). Together with transcriptome 
sequencing, microRNA expression and DNA methylation data, as well as data from other studies 
(32-35), the authors analyzed information from a total of 1,332 breast cancers. Utilizing a list of 
727 known human cancer genes (not specific to BrCa), this study found the 10 most frequently 
mutated genes in these 1,332 BrCa cases: TP53, PIK3CA, MYC, CCND1, PTEN, ERBB2, GATA3, 
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RB1, MAP3K1, and chr8:ZNF703/FGFR1 (1). These 10 common BrCa mutations accounted for 
62% of the total 194 driver mutations found.  
Modern day technologies that disrupt gene expression of a specific target serve as very 
powerful analytical tools in scientific research. One such tool developed in recent years is 
known as CRISPRi (clustered regularly interspaced short palindromic repeat interference). The 
system was discovered in bacteria, when three groups noticed that some CRISPR spacers were 
identical to sequences of viruses (37). A deeper look into the CRISPR array found that CRISPR-
Cas (CRISPR associated proteins) systems are responsible for adaptive immunity in bacteria, 
with the ability to acquire fragments of foreign DNA and incorporate them into the genome to 
allow for sequence-specific resistance and degradation if that foreign DNA target were to 
invade the cell again (37). The CRISPR-Cas system has come to the forefront of research 
investigations interested in gene function, developmental pathways, and mechanisms of 
disease. In this project, inducible CRISPRi-dCas9-KRAB was utilized to specifically repress and 
knockdown the expression of RUNX1 in the MCF10A breast cancer cell series.  
Another modern day technology critical to loss-of-function studies and gene depletion 
analyses is known as RNA interference (RNAi). The mechanism at work in RNAi is based on the 
sequence-specific degradation or translation interference of mRNA through the cytoplasmic 
delivery of double-stranded RNA that carries the identical sequence to the target gene (38). 
Target-specific degradation is achieved by use of the cell’s endogenous RNA-induced silencing 
complex, commonly known as RISC, as well as the endogenous enzyme known as Dicer. Gene 
silencing is also achieved by siRNA  binding the target mRNA to physically interfere with the 
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cell’s translation machinery (39). In this project, shRNA was successfully utilized to knockdown 
the expression of RUNX1 in the MCF10 breast cancer cell series at the transcriptome level.  
Future directions for this project include investigating the mechanism by which RUNX1 
suppresses tumor progression. In response to RUNX1 knockdown, this project will analyze the 
downstream effects of genes known to be activated or suppressed as cancer progresses, 
commonly known as cancer driver genes. Through identification of potential BrCa driver genes 
regulated by RUNX1, further studies may investigate the role these genes have in the BCSC 
population; contributing important evidence for potential targets for modern, safe, and 
efficient BrCa therapies.  
Methods 
 
Tissue Culture 
 
The MCF10A (10A) cell progression model was used for all experiments in this study. 
The MCF10 breast cancer cell progression series is derived from benign breast tissue from a 
woman with fibrocystic breasts. The MCF10A cells are immortalized, normal-like and non-
malignant, attached epithelial cells, while the MCF10AT1 (AT1) cells are derived from MCF10A 
cells transformed with constitutively activated H-RAS, resulting in premalignant cells capable of 
neoplasm progression. The MCF10CA1a (CA1a) cells are the final cells in the progression, which 
are fully malignant, readily forming large tumors and capable of metastasizing. All three cell 
lines were produced from the same patient and thus have a similar genetic background.  
The media used for both 10A and AT1 cells consisted of DMEM/F12 (Hyclone-
SH30271.02) and 5% horse serum (Gibco 16050 lot #1075876) and 10ug/ml of human insulin 
(Sigma I-1882) and 20ng/ml of human epidermal growth factor and 100ng/ml of cholera toxin 
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(Sigma C-8052) and 0.5 ug/ml of Hydrocortisone (Sigma H-0888) and Pen/Strep, and L-
Glutamine.  
Cells were cultured in growth media, which was replaced every 24-48 hours by 
removing the old media and replacing with the new media warmed to 37°C. For a 100mm petri 
dish, 10mL of media was used. As the culture reached 75-80% confluency, the cells were 
passaged using a splitting ratio of approximately 1:10. The cells were passaged every 2-4 days 
as the cell density approached approximately 7-10 x 106 cells per 100mm dish. The seeding 
density for plating cells was approximately 1-2 x 106 cells per 100mm dish. All cell cultures were 
maintained at 37°C.  
CRISPRi Oligo Design and Cloning  
The CRISPRi-dCas9 system utilizes a doxycycline-inducible deactivated Cas9 protein 
fused to a KRAB (Krüppel-associated box) repression domain, targeting the RUNX1 gene and, 
upon addition of doxycycline, prevents transcription of nascent RUNX1 mRNA (40) (Figure 6). In 
the inducible CRISPRi system the target is not cleaved or excised, rather it is silenced and 
repressed when doxycycline is present. This is because the Cas9, which holds helicase and 
nuclease activity, has been deactivated (dCas9), resulting in a physical steric block that halts 
transcription elongation by RNA polymerase (41). 
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This differs from the original CRISPR system developed in 2012, which uses active RNA-
guided nucleases to recognize, cleave and degrade any foreign genetic elements (40). The 
complete system is composed of CRISPRi dCas9-KRAB with a highly specific single guide RNA 
(sgRNA) for the target gene of interest. Additionally, the target locus must contain a specific 
protospacer adjacent motif (PAM) sequence, which in this case is NGG, where N is any 
nucleotide (40). The ability for inducible CRISPRi to be highly programmable for the target gene 
as well as completely reversible lends it to be one of the most useful tools in depletion and loss-
of-function studies. 
Guide RNAs were chosen to target between 300 base pairs upstream and 100 bases 
downstream of the RUNX1 transcription start site using the online tool Benchling CRISPR 
design. Three guides, each of 20 base pairs, were designed for each RUNX1 promoter of 
interest, denoted P1 and P2 (Table 1). All plasmids contained the same overhangs following 
digestion and were used for cloning into lentiCRISPRv2 (or lentiCRISPRv1). The overhangs were 
designed as shown below.  
Image Source: Qi Lab, UCSF 
Figure 6: The Inducible CRISPRi-dCas9 System Halts Transcription Elongation by Interfering with 
RNA Polymerase. Upon dCas9 induction via doxycycline, dCas9 identifies a PAM sequence along 
with a gene target using a specific sgRNA sequence. Once bound, dCas9-KRAB block transcription 
of the target gene, generating a depletion of the target gene.  
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5’ – CACCGNNNNNNNNNNNNNNNNNNN – 3’  
                  3’ – CNNNNNNNNNNNNNNNNNNNCAAA – 5’ 
 
 
Standard de-salted oligos were ordered from Invitrogen and resuspended to 100µM in 
sterile water. Oligos were stored at -20°C. For each construct, each oligo pair was 
phosphorylated and annealed. 1µl of 100µM oligo 1 was combined with 1µl of 100µM oligo 2, 
1µl 10X T4 Ligation Buffer, 0.5µl T4 PNK (NEB M0201S), and 6.5µl ddH2O. The oligos were 
annealed in a thermocycler at 37°C for 30 minutes followed by 5 minutes at 95°C and 
subsequently ramped down to 25°C at 0.1°C/sec. The annealed oligos were pooled and diluted 
1:250.  
The digestion-ligation reaction was set-up by combining a variable volume of lentiguide-
puro or other backbone vector (100ng), 2 µl of diluted phosphorylated and annealed oligo 
duplex, 2 µl 10x FastDigest Buffer, 1 µl 10mM DTT, 1 µl 10 mM ATP, 1 µl FastDigest Esp3I 
(Thermo Fisher), 0.5 µl T7 DNA ligase, and a variable volume of ddH2O for a combined total of 
Table 1: Design of Six CRISPRi Constructs Targeting Promoter 1 (P1) and Promoter 2 (P2) of 
hRUNX1. Benchling CRISPR Design was utilized to target the RUNX1 transcription start site and 
the automated DNA sequencing of the guides was performed in the University of Vermont 
Cancer Center Advanced Genome Technologies Core.  
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20µl. A negative control digest using H2O was also established for the reaction. The ligation 
reaction was incubated in a thermocycler for 5 minutes at 37°C followed by 5 minutes at 23°C, 
and these two steps were repeated through six total cycles and held at 4°C. The exonuclease 
treatment reaction consisted of 11µl of the ligation reaction, 1.5µl 10X PLasmidSafe Buffer, 
1.5µl 10 mM ATP, and 1µl PlasmidSafe DNase and was incubated at 37°C for 30 minutes.  
Plasmid (2µl) was transformed into 50µl of Stbl3 cells (Thermo Sci NC9046399) following 
mix-and-go protocol. The cell suspension (50µl) was plated on plates containing ampicillin. The 
following day, individual, homogenous bacteria cultures were selected using a sterile pipette.  
shRNA-mediated Knockdown 
Since the conception of early RNAi methods, such as small interfering RNA (siRNA), 
methods have evolved to use shRNA. shRNA constructs are capable of DNA integration and are 
therefore more stable and suitable for gene knockdown than siRNA (38).  In shRNA, target 
constructs are infected into the cell using virally produced vectors or are transfected as plasmid 
vectors into the cell. The shRNAs consist of 19-22bp sequences linked by a short loop of 
nucleotides akin to that of the hairpin structure found in naturally occurring microRNA. After 
transcription of the newly integrated shRNA, the shRNA sequence is exported to the cytosol 
where it is bound by the Dicer enzyme. Dicer then processes the shRNA into siRNA duplexes 21-
23 nucleotides long having 2-nucleotide-long 3’-overhangs on each strand, which subsequently 
bind the target mRNA for incorporation into the RISC complex or bind to physically prevent 
translation from occurring. RISC then unwinds the double-stranded siRNA and selects the 
antisense (guide) strand that is complementary to the knockdown target. Finally, RISC and the 
catalytically active subunit Argonaute protein family member (Ago) carry out the slicing function 
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by cleaving the RNA transcript that is paired to the guide strand. This cleaving action therefore 
prevents the expression of the gene product (Figure 7) (38, 42).   
Recent studies achieving gene knockdown in mammalian cells have employed shRNA over 
siRNA for a few reasons (39, 43, 44). One major concern with siRNA is off-target effects due to 
the high concentration of siRNA in the cytoplasm. Though improved, this remains a concern for 
shRNA (38). Another major concern for siRNA is that as the cells divide, the siRNA concentration 
can become diluted, which can pose a significant issue with rapidly dividing cancer cells such as 
MCF10AT1. shRNA is preferred for this gene knockdown study because it can be used to create 
a stable cell-line via drug selection such as puromycin and fluorescent markers such as GFP that 
may be used for FACS (38). 
Figure 7: shRNA-Mediated Gene Silencing. The 
shRNA is exported to the cytosol where it is 
processed into siRNA duplexes that target the gene 
of interest for degradation via RISC (7).  
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Plasmid Isolation 
Plasmid DNA was isolated using Zymo Research ZymoPURE Plasmid Midiprep Kit 
(D4200). This kit utilizes a modified alkaline lysis method of plasmid purification and ensures 
the plasmid is free of endotoxins, salts, proteins and RNA. Therefore, the prepared plasmids are 
suitable for transfection, transformation, PCR amplification and DNA sequencing. The kit was 
used according to manufacturer’s instructions using the centrifugation method. The nucleic acid 
concentrations of each plasmid were analyzed using the ThermoFisher NanoDrop 2000 UV-Vis 
spectrophotometer.  
Virus Production 
 
HEK293T cells were maintained in Dulbecco’s Modified Eagle Medium (Gibco, 11965) 
supplemented with 10% fetal bovine serum (Valley Biomedical, BS3033). HEK293T cells were 
split and plated at 1.3×105 cells/cm2. The following day, packaging plasmids and dCas9 or 
sgRNA-coding plasmids were transfected using Lipofectamine 2000 transfection reagent 
(Invitrogen, 11668500) into HEK293T cells in Opti-MEM (Gibco, 31985) according to the 
manufacturer’s instructions. Virus was harvested 48 hours after transfection. Plasmids 
containing either CRISPRi guide RNA or shRNA-RUNX1 were then transduced into 10A or AT1 
cells. For inducible CRISPRi, dCas9 expression was induced by the addition of the antibiotic 
doxycycline. Fresh doxycycline was added to fresh media at the concentration of 2µM every 24 
hours to maintain dCas9 expression and therefore maintain the inhibition of RUNX1 by CRISPR.  
shRNA Knockdown: Infection  
Lentivirus-based RNAi transfer plasmids with pGIPZ shRUNX1 (clone V2LHS_150257 and 
V3LHS_367631, GE Dharmacon) and pGIPZ non- silencing (Cat No. RHS4346, GE Dharmacon) 
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were purchased from Thermo Scientific. To generate lentivirus vectors, 293T cells in 10 cm 
culture dishes were co- transfected with 10 μg of pGIPZ shRUNX1 or pGIPZ non- silencing, with 
5 μg of psPAX2, and 5 μg of pMD2.G using lipofectamine 2000 reagent (Life Technologies). 
Viruses were harvested every 48 h post-transfection. After filtration through a 0.45 μm-pore-
size filter, viruses were concentrated by using LentiX concentrator (Clontech, Mountain View, 
CA, USA).  
Gene delivery by transfection and infection  
For shRNA-mediated knockdown of RUNX1 expression, MCF10A or MCF10AT1 cells 
were plated in six- well plates (1x105 cells per well) and infected 24 hours later with lentivirus 
expressing shRUNX1 or non-silencing (NS) shRNA. Briefly, cells were treated with 0.5 ml of 
lentivirus and 1.5 ml complete fresh DMEM-F12 per well with a final concentration of 4 μg/ml 
polybrene. Plates were centrifuged upon addition of the virus at 1460 × g at 37°C for 30 min. 
Infection efficiency was monitored by GFP co-expression at 2 days post infection. Cells were 
selected with 2 μg/ml puromycin (Sigma Aldrich P7255- 100MG) for at least two additional 
days. After removal of the floating cells, the remaining attached cells were passed, harvested 
for protein or RNA, and analyzed.  
Western Blot Analysis 
 
I. Sample Harvest and Preparation 
 
The cell culture of interest for protein analysis was harvested and lysed using 100-400µl 
of ice-cold 1X RIPA per 10cm dish (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b–
glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) supplemented with complete, EDTA-free 
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protease inhibitors (Roche Diagnostics) and the proteasome inhibitor MG132 (EMD Millipore 
San Diego, CA, USA). Using a cell scraper, the cells were scraped and transferred to a 
microcentrifuge tube and snap frozen in liquid nitrogen. The samples were kept at -80°C until 
ready for analysis. 
Each sample was then sonicated at an amplitude of 30 (Q700 Sonicator System, QSonica 
Sonicators, Newtown, CT). Samples were subjected to a cycle of 10 seconds of sonication 
followed by 30 seconds of rest on ice slurry, for a total of seven cycles (QSonica Microtip #4418, 
1/8” Diameter). Samples were then centrifuged for 20 minutes at 15,000 RPM. 6µl of 
supernatant was removed and diluted 10-fold in 1X RIPA for use in the BCA assay (see below). 
The remainder of the supernatants were diluted in 5X loading dye and boiled for 5 minutes, 
placed on ice for 1 minute, and stored at -80°C.  
II. Bicinchoninic Acid Assay (BCA Assay): Protein Quantification and Internal Controls 
 
The Thermo Scientific Pierce BCA Protein Assay was utilized as a method to accurately 
quantify the total amount of protein present in a sample. Protein standards using bovine serum 
albumin (BSA) are prepared in order to quantify the sample protein concentrations based on 
the absorbance at 562nm.  
In a 96-well plate, BSA standards diluted in 1X RIPA with concentrations of 0.5µg/ml, 
0.25µg/ml, 0.125µg/ml, 0.0625µg/ml, and 0.03125µg/ml were prepared. One blank consisting 
of 1X RIPA was also prepared. Enough BCA working reagent was prepared in order for each 
sample, measured in duplicate, and each standard to have 200µl. 50 parts of BCA reagent A was 
mixed with 1 part of BCA reagent B. 200µl of working reagent was added to each well to be 
measured. 25µl of each sample to be measured, including the standards, was loaded into an 
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individual well and mixed thoroughly by pipetting (1:8 to the working reagent). The plate was 
incubated for 30 minutes at 37°C. The plate was read using a plate reader at 562nm.  
To quantify the protein concentration of each sample, a standard curve of known BSA 
concentration vs. absorbance at 562 nm was generated. A computer-generated linear trend line 
was added, displaying the slope and y-intercept values. The unknown samples were adjusted 
for the value of the blank’s absorbance and averaged for each replicate.  Using the linear trend 
line, each unknown’s absorbance value was solved for x, the protein concentration. The 10-fold 
dilution was accounted for, and the resulting value was multiplied by 1/40 to yield the 
appropriate loading volume for 40µg of protein for the western blot.  
III. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) & Protein 
Transfer  
 
The cell lysate samples were separated in an 8.5% acrylamide gel using polyacrylamide 
gel electrophoresis and subsequently subjected to immunoblotting. The completed gels were 
transferred to PVDF membranes (EMD Millipore) using an overnight wet transfer apparatus 
(Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked using 5% bovine 
serum albumin (BSA) or 5% milk + 0.02% sodium azide (Sigma-Aldrich) and incubated overnight 
at 4°C with the primary antibody. The Clarity Western ECL Substrates (Bio-Rad Laboratories) 
were used 1:1 for immunodetection of HRP and imaged on a Chemidoc XRS+ imaging system 
(Bio-Rad Laboratories). A full summary of antibodies used as well as their dilutions can be found 
in table 2. To determine the relative expression of the target protein relative to the control 
protein b-actin, FIJI (ImageJ) software was used to perform densitometry analyses. The FIJI 
software determined density peaks for each protein band and calculated the area under each 
peak. The peak values for each b-Actin band were then used with the peak values for the target 
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protein bands to calculate a ratio that represented the change in expression of the protein of 
interest relative to b-Actin. This method allowed for the selection of only the target protein 
bands, however it did not allow for the standardization of background signaling that may have 
occurred proximal to each band.  
Table 2: Summary of antibodies and dilution factors used for western blot protocols.  
 
shRNA Controls: Reporter Gene GFP Sorting and Puromycin Selection 
 
 To maintain an efficient and high-quality RUNX1 knockdown, the infected cells were 
sorted via FACS based on relative expression of the pGIPZ reporter gene TurboGFP. The cells 
were collected and resuspended in sterile PBS with 5% horse serum and DAPI (1:5000) and 
subsequently sorted and plated. GFP efficiency and cell vitality was checked 24 hours later 
(Figure 8). To further maintain RUNX1 knockdown, the sorted cells underwent a one-week 
period of puromycin selection. Normal media was replaced with media containing 2µg/mL 
puromycin. Cells expression the GIPZ plasmid will express both the shRNA as well as resistance 
Target Primary/Secondary Species Catalog No. Company Lot No. Dilution Factor
RUNX1 Primary Rabbit 4336S Cell Signaling 4 1:1000
RUNX1 Secondary Goat Anti-Rabbit HRP 3140 ThermoFisher Scientific (Invitrogen) SA245916 1:3000
PIK3CA Primary Rabbit 4249 Cell Signaling 9 1:1000
PIK3CA Secondary Goat Anti-Rabbit HRP 3140 ThermoFisher Scientific (Invitrogen) SA245916 1:3000
PIK3R1 Primary Rabbit 4257 Cell Signaling 6 1:1000
PIK3R1 Secondary Goat Anti-Rabbit HRP 3140 ThermoFisher Scientific (Invitrogen) SA245916 1:3000
HA TAG dCAS9 Primary Rabbit 3724 Cell Signaling 8 1:1000
HA TAG dCAS9 Secondary Goat Anti-Rabbit HRP 3140 ThermoFisher Scientific (Invitrogen) SA245916 1:3000!-Actin Primary Mouse 3700S Cell Signaling 10 1:5000!-Actin Secondary Goat Anti-Mouse HRP 31430 ThermoFisher Scientific (Invitrogen) SD251027 1:5000
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to the antibiotic puromycin. The media was replaced every 24 hours to remove any floating and 
dead cells and to replace with fresh media.  
Quantitative PCR (qPCR) 
RNA was harvested from cells and isolated with Trizol (Life Technologies). The samples 
were cleaned by DNase I digestion (Zymo Research, Irvine, CA, USA). RNA was reverse 
transcribed using SuperScript IV and random hexamers (Life Technologies). The cDNA was 
further cleaned with RNA removal via E. coli RNase H treatment (Life technologies). cDNA was 
then subjected to quantitative PCR using SYBR Green technology (Applied Biosystems, Foster 
City, CA, USA). The genes selected for qPCR analysis for this project were chosen based on 
unpublished ChIP-Sequencing data (Andrew Fritz) that first identified where in the genome 
RUNX1 binds. Additionally, unpublished RNA-sequencing data (Andrew Fritz) was used to 
determine the change in expression of genes upon RUNX1 depletion. This information, 
combined with genes known to drive BrCa (1), identified BrCa driver genes that may be under 
RUNX1 regulatory control due to proximal binding to the gene transcription start site and due 
to change in expression upon loss of RUNX1. A summary of primer sequence for these genes 
can be found in table 3.  
Figure 8: GFP Expression in MCF10A shRNA-Mediated Knockdown. Expression of the pGIPZ 
reporter gene GFP was analyzed using fluorescence microscopy to determine preliminary 
RUNX1 knockdown efficiency. Non-silencing shRNA (A), shRUNX1 C1 (B), and shRUNX1 C4 (C).  
8A 8B 8C 
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Table 3: Summary of primer sequences used for quantitative PCR protocols.  
 
Results 
 The central objective of this project was to first develop a RUNX1 loss of function model 
in human BrCa cells (10A and AT1) using inducible CRISPRi and shRNA. Upon RUNX1 loss, this 
study aimed to investigate how RUNX1 may be involved in the expression of predicted BrCa 
driver genes based on preliminary RUNX1 ChIP-seq data, RNA-seq data, and the published 
literature identifying BrCa driver genes (1). The long-term goal of this project is to therefore 
identify BrCa driver genes putatively regulated by the tumor suppressor action of RUNX1.  
 
 
Target Forward Sequence Reverse Sequence
SF3B1 GTGGGCCTCGATTCTACAGG GATGTCACGTATCCAGCAAATCT
PIK3R1 ACCACTACCGGAATGAATCTCT ACCACTACCGGAATGAATCTCT
KRAS ACAGAGAGTGGAGGATGCTTT TTTCACACAGCCAGGAGTCTT
FOXA1 GCAATACTCGCCTTACGGCT TACACACCTTGGTAGTACGCC
PIK3CA CCACGACCATCATCAGGTGAA CCTCACGGAGGCATTCTAAAGT
TP53 CAGCACATGACGGAGGTTGT TCATCCAAATACTCCACACGC
PTEN TGGATTCGACTTAGACTTGACCT GGTGGGTTATGGTCTTCAAAAGG
USP9X TCGGAGGGAATGACAACCAG GGAGTTGCCGGGGAATTTTCA
ATM ATCTGCTGCCGTCAACTAGAA GATCTCGAATCAGGCGCTTAAA
APC AAAATGTCCCTCCGTTCTTATGG CTGAAGTTGAGCGTAATACCAGT
PBRM1 AGGAGGAGACTTTCCAATCTTCC CTTCGCTTTGGTGCCCTAATG
BUB1B AAATGACCCTCTGGATGTTTGG GCATAAACGCCCTAATTTAAGCC
GAPDH TGTGGTCATGAGTCCTTCCA ATGTTCGTCATGGGTGTGAA
RUNX1 AACCCTCAGCCTCAGAGTCA CAATGGATCCCAGGTATTGG
CDH1 GGAAGTCAGTTCAGAGCATC AGGCCTTTTGACTGTAATCACACC
ACTIN-B AGCACAGAGCCTCGCCCTT CGGCGATATCATCATCCA
N-CADHERIN TGTTTGACTATGAAGGCAGTGG TCAGTCATCACCTCCACCAT
VIMENTIN AGGAAATGGCTCGTCACCTTCGTGAATA GGAGTGTCGGTTGTTAAGAACTAGAGCT
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Doxycycline-Induced CRISPRi Knockdown of RUNX1 
 Previous work carried out by Alexandra Ojemann in the Stein/Lian laboratory 
successfully isolated stable clonal populations of AT1 cells infected with the CRISPRi-dCas9-
KRAB system. Upon addition of varying concentrations of the antibiotic doxycycline to cells in 
culture, dCas9 expression at the protein level was determined among four sets of clones 
denoted as clones 1, 4, 5, and 6. Doxycycline induction was carried out for three days with 
concentrations of 2µM, 5µM, and 10µM. In response to doxycycline, dCas9 was expressed at 
the protein level, as determined by western blot analysis (Figure 9). The uninduced samples 
 (doxycycline = 0µM) were found to express no dCas9 (Figure 9).  
 
 
 
Figure 9: Upon Dox-Induction, AT1 Cells Transfected with CRISPRi Plasmid pLV hU6-sgRNA 
hUbC-dCas9-KRAB-T2a-GFP Expressed dCas9. dCas9 was expressed at the protein level in AT1 
clones 1, 4, 5 and 6. Dox concentrations of 2µM, 5µM, and 10µM all demonstrated dCas9 
expression. Standard western blot protocol was followed, and the antibody used was HA Tag 
3724 Lot #8 Rabbit mAb (Cell Signaling).  
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Relative to b-Actin expression, which was used as an internal control, dCas9 expression 
among the AT1 clones did not directly correlate with doxycycline concentration. Higher 
doxycycline concentration did not consistently result in a greater expression in dCas9 (Figure 
10). In some AT1 clones, 2µM doxycycline was just as, or more, effective in inducing dCas9 
expression than 10µM doxycycline. A complete summary of dCas9 expression at the protein 
level upon the addition of doxycycline over the course of three days is included in Table 4.  
 
 
 
 
 
 
Figure 10: Doxycycline Concentration and dCas9 Expression do not Directly Correlate. Varying 
concentrations of doxycycline resulted in varying levels of dCas9 expression in AT1 clone 5 (7A) as well 
as AT1 clone 4 (7B) at the protein level. Expression was determined via western blot analysis relative to 
b-actin expression. One western blot was analyzed for each clone for each of three doxycycline 
concentrations.   
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Table 4: Doxycycline-Induced AT1 Clones Expressed dCas9 Protein. Upon addition of 2µM, 5µM, and 
10µM doxycycline, AT1 clones 1,4,5 and 6 expressed dCas9 at the protein level. Doxycycline was 
replenished every 24 hours for 72 hours total. Standard western blot protocol was followed, and 𝛃-
Actin served as a control. Using FIJI software, densitometry analysis was performed to yield the 
expression of the dCas9 signal relative to b-Actin. HA Tag (dCas9) Primary Antibody: Rabbit mAb HA 
Tag #3724 Lot 8 (Cell Signaling). b-Actin Primary Antibody: b-Actin Mouse mAb #3700S Lot 10 (Cell 
Signaling) 
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Further AT1 clonal analysis was carried out to determine RUNX1 protein expression in 
each of the four clones expressing dCas9 upon dox-induction. The first round of CRISPRi-
mediated RUNX1 knockdown demonstrated a clear need for CRISPRi optimizations. Among AT1 
clonal populations expressing the dCas9 plasmid, RUNX1 expression at the protein level varied 
drastically between doxycycline concentrations and between consecutive days after infection 
with the sgRNA CRISPRi guides targeting RUNX1 (Figure 11). A consistent knockdown trend was 
not seen throughout the three days of doxycycline induction in any of the clones or at any 
specific doxycycline concentration (Figure 12). 
Figure 11: Upon Dox-Induction, AT1 Cells Infected with CRISPRi Plasmid pLV hU6-sgRNA hUbC-
dCas9-KRAB-T2a-GFP Expressed Variable Levels of RUNX1. AT1 clones 4 and 5 expressed 
varying levels of RUNX1 at the protein level upon three days of doxycycline induction of varying 
concentrations. Standard western blot protocol was followed. The RUNX1 antibody used was 
AML1 Rabbit mAb #4336S Lot 4 (Cell Signaling). b-Actin served as a control, mouse mAb #3700S 
Lot 10 (Cell Signaling).  
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Based on the variability of RUNX1 knockdown, the CRISPRi-dCas9 system was optimized 
at the level of the virus production and the subsequent infection of the AT1 cells. We 
hypothesized that increasing the quantity of virus would result in a more efficient and 
consistent gene knockdown.  
Increasing the Virus Titer of CRISPRi Targeting RUNX1 Yielded Greater Knockdown Efficiency 
In order to gain a more significant and consistent knockdown of RUNX1 upon the 
addition of doxycycline, the virus titer containing the sgRNA targeting RUNX1 was increased 
five-fold. We hypothesized that a higher virus titer would result in a better knockdown of 
RUNX1, as the infection efficiency would likely increase. Based on previous clonal protein 
expression of RUNX1, clone 4 was selected to test the high virus titer CRISPRi knockdown. In 
previous experiments, AT1 clone 4 was the only clone that displayed a consistent downward 
trend of RUNX1 expression as the time progressed (Figure 12). Therefore, clone 4 was theorized 
Figure 12: Upon Dox-Induction, AT1 Cells Infected with CRISPRi Expressed Variable Levels of RUNX1. 
AT1 clones 4 (10A) and 5 (10B) expressed varying levels of Runx1 at the protein level upon three days 
of doxycycline induction of concentrations 2µM, 5µM, and 10µM. Standard western blot protocol was 
followed and the RUNX1 antibody used was AML1 Rabbit mAb #4336S Lot 4 (Cell Signaling). b-Actin 
served as a control, mouse mAb #3700S Lot 10 (Cell Signaling).  
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to best show RUNX1 depletion upon infection with a five-fold increase in virus.  After infection 
of the sgRNA RUNX1 guides and upon addition of 2µM doxycycline every 24 hours for three 
days, AT1 clone 4 displayed an appreciable net loss of RUNX1 at the protein level (Figure 13). 
Samples were run in duplicate, generating a standard error of the mean. Replicate A 
demonstrated a consistent and significant depletion in RUNX1 as time progressed, while 
Replicate B showed RUNX1 depletion on days one and three with an increase in RUNX1 
expression on day two, relative to b-actin (Figure 14). However, this is also true for the non-
induced control of 0µM doxycycline (Figure 14). In both control replicates, RUNX1 expression 
increased on day two and decreased again on day three (Figure 13, Figure 14). A potential 
consideration for this result is that RUNX1 may exert a compensatory mechanism to combat the 
repressive effects on the inducible CRISPRi dCas9-KRAB system to therefore maintain adequate 
expression of RUNX1 in the cells, though additional biological replicates must be carried out to 
fully investigate this finding.   
 
 
 
Figure 13: Doxycycline-Induced RUNX1 CRISPRi Knockdown in MCF10AT1 Clone 4 cells. RUNX1 
expression was analyzed via Western Blot analysis. Two replicates of AT1 cells were carried out 
and 2µM Doxycycline was added every 24 hours for a 72-hour period. Samples were harvested 
every 24 hours using 1X RIPA and standard RUNX1 Western Blot protocol was followed. RUNX1 
antibody used: AML1 Rabbit mAb #4336S Lot 4 (Cell Signaling). b-Actin served as a control mouse 
mAb #3700S Lot 10 (Cell Signaling).  
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 In four AT1 clonal populations previously developed by Alexander Ojemann of the 
Stein/Lian group, dCas9 was expressed upon doxycycline-induction as early as 24 hours and at a 
concentration as low as 2µM (Table 4). dCas9 expression therefore confirmed successful 
transfection of the dCas9-KRAB plasmid and allowed for dox-induced RUNX1 gene silencing 
studies to be performed. Initial doxycycline induction in AT1 clone 4 did not yield significant 
knockdown of RUNX1, as RUNX1 expression was highly variable between 24-hour harvest 
Figure 14: Doxycycline-Induced RUNX1 CRISPRi Knockdown in MCF10AT1 Clone 4 cells (Viral 
Construct 5). RUNX1 protein expression was analyzed via Western Blot and quantified in 
relation to b-actin expression. Two replicates of AT1 cells were performed and 2µM 
Doxycycline was added every 24 hours for a 72-hour period. Samples were harvested every 24 
hours using 1X RIPA and standard RUNX1 Western Blot protocol was followed. Using FIJI 
software, densitometry analysis was performed to yield the expression of the RUNX1 signal 
relative to b-Actin.  Error bars represent the standard error of the mean (SEM).   
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points and between doxycycline concentrations used for induction (Figure 14). To optimize the 
inducible CRISPRi system, five times the quantity of virus carrying the sgRNA guides targeting 
RUNX1 was generated in HEK293T cells. Upon infection, RUNX1 knockdown improved 
compared to previous studies, but did not show consistency or validity compared to the 
uninduced control samples (Figure 14). For these reasons, and due to time constraints, the 
CRISPRi-mediated knockdown system was no longer pursued, and we began developing a 
RUNX1 knockdown system using shRNA in order to perform downstream genomic analyses in 
cells depleted of the RUNX1 transcription factor.    
shRNA-Mediated Knockdown of Runx1  
 
 A second gene knockdown tool, shRNA, was utilized in the 10A series in order to gain a 
more complete and consistent depletion of RUNX1. The shRNA system has proven effective and  
 
Figure 15: Protein expression profile of MCF10A and MCF10AT1 upon shRNA knockdown 
targeting RUNX1. GFP+ 10A and AT1 cells were selected for via FACS and standard western 
blot protocol for RUNX1 was followed. NS: shRNA non-silencing construct. shRUNX1-1: 
shRNA RUNX1 knockdown construct. RUNX1 AML1 Rabbit mAb #4336S Lot 4 (Cell 
Signaling) 𝛃-Actin served as a control mouse mAb #3700S Lot 10 (Cell Signaling).   
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successful in our lab and was therefore the method of choice to mediate RUNX1 depletion in a 
timely manner (3).   
Knockdown of RUNX1 in both 10A and AT1 cells by shRNA proved effective at the 
protein level. Western blot analysis determined that RUNX1 was decreased over 70% relative to 
the non-silencing shRNA in both the 10A and AT1 cells (Figure 15, Figure 16).  
Short hairpin RNA knockdown also proved efficient at the RNA level. qPCR was carried 
out for cDNA of shRunx1 AT1 cells to determine the RNA expression of RUNX1 as well as E-
cadherin (CDH1) following depletion of RUNX1. Expression change relative to the housekeeping 
Figure 16: RUNX1 protein expression change upon shRUNX1 knockdown in 10A and 
AT1 cells. Relative to 𝛃-Actin, RUNX1 was depleted by 72% in 10A cells (n=1) and 77% 
in MCF10AT1 cells (n=1) using shRUNX1-1. NS: shRNA non-silencing construct. 
shRUNX1-1: shRNA RUNX1 knockdown construct. Using FIJI software, densitometry 
analysis was performed to yield the expression of the RUNX1 signal relative to b-Actin.   
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gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as well as the non-silencing (NS) 
construct yielded DDCT values for gene expression of RUNX1 and CDH1. Fold expression change 
was calculated by raising (-DDCT) to the power of 2. In AT1 cells, RUNX1 depletion resulted in a 
loss of the epithelial marker CDH1, lending further support to previous findings that RUNX1 loss 
advances the mesenchymal phenotype and EMT (Figure 17).  
To investigate the role of RUNX1 as a tumor suppressor, potential BrCa driver genes 
were identified using unpublished ChIP-seq and RNA-seq data from the Stein/Lian lab (Andrew 
Fritz). The ChIP-seq data identified where in the genome RUNX1 is normally bound, while the 
RNA-seq data identified the change in expression of genes upon RUNX1 depletion. Together 
Figure 17: shRNA-Mediated Knockdown of RUNX1 Decreases CDH1 Expression at the RNA 
Level in AT1 Cells. Upon shRNA-mediated knockdown of RUNX1, qPCR analysis determined 
that CDH1 decreased at the mRNA level. Gene expression levels are relative to GAPDH as 
well as the non-silencing (NS) shRNA construct. Error bars represent SEM. qPCR was run in 
duplicate for two biological replicates. 
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with this, as well as data published from Serena Nik-Zainal and colleagues (1), we identified top 
BrCa driver genes with transcription start sites that RUNX1 proximally binds to and that RUNX1 
may exert regulatory control over (Table 5). This yielded a list of 11 BrCa driver genes that 
change in expression upon RUNX1 depletion and contain transcription start sites at which 
RUNX1 binds.  
After successful depletion of RUNX1 in 10A and AT1 cells using shRNA, the regulatory 
action of RUNX1 on these specific BrCa driver genes was investigated. Phosphatidylinositol-4,5-
Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) and Phosphoinositide-3-Kinase 
Regulatory Subunit 1 (PIK3R1) are two kinase protein components that are part of the same 
kinase protein complex and that were determined to be commonly mutated in BrCa and 
therefore identified as BrCa driver genes (1). Upon RUNX1 depletion, the RNA and protein 
expression profiles of these specific kinases were analyzed to determine if PIK3CA and PIK3R1 
are under the regulatory control of RUNX1. qPCR data revealed that RUNX1 knockdown 
resulted in an increase in both PIK3CA and PIK3R1 RNA expression compared to non-silencing 
(Figure 18). At the protein level, RUNX1 depletion in AT1 cells resulted in an increase in PIK3CA 
Table 5: Based on whole-genome 
analysis of 1,332 breast cancers, 
driver genes based on mutation 
frequency were found (1). 
Subsequent analysis based on 
driver gene rating, distance from 
gene TSS to RUNX1 binding, and 
change in expression upon 
RUNX1 depletion generated a 
subset of BrCa driver genes that 
may be under the control of 
RUNX1.   
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(Figure 19). Conversely, RUNX1 depletion did not significantly alter the protein expression of 
PIK3R1 (data not shown).  
 
 
 
 
 
 
Figure 19: Expression of PIK3CA protein increased upon 
RUNX1 knockdown in AT1 cells. Western blot analysis 
determined that upon shRNA knockdown of RUNX1 in AT1 
cells there was an increase in PIK3CA protein expression, 
suggesting RUNX1 exerts regulatory action on PIK3CA’s 
function in BrCa. Standard western blot protocol was 
followed, and b-Actin served as a control. NS: shRNA non-
silencing construct. shRUNX1-1: shRNA RUNX1 knockdown 
construct.  Primary antibodies used: RUNX1 AML1 Rabbit 
mAb #4336S Lot 4 (Cell Signaling); PIK3CA Rabbit mAb #4249 
(Cell Signaling); b-Actin Mouse mAb #3700S Lot 10 (Cell 
Signaling).  
 
Figure 18: Expression of PIK3CA/R1 Increased upon RUNX1 Knockdown in 10A Cells. qPCR determined 
that upon shRNA knockdown of RUNX1 in 10A cells there was an increase in PIK3CA and PIK3R1 mRNA 
expression, suggesting a role for RUNX1 in regulating PI3K kinase functions in BrCa. Error bars represent 
the SEM. NS: shRNA non-silencing construct. shRUNX1-1: shRNA RUNX1 knockdown construct 1. 
shRUNX1-2: shRNA RUNX1 knockdown construct 2.   
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 The shRNA knockdown system targeting RUNX1 proved effective in depleting RUNX1 at 
the transcriptomic level. In 10A and AT1 cell models, representing both normal-like and tumor-
like cells, RUNX1 was decreased by approximately 70% (Figure 16). This level of RUNX1 
depletion resulted in a decrease in RNA expression of the epithelial marker E-cadherin (Figure 
17) and an increase in the RNA expression of PIK3R1 (Figure 18) and an increase in both the 
RNA and protein expression of PIK3CA (Figure 18, Figure 19). These preliminary results suggest 
that RUNX1 may exert regulatory control over the PI3K signaling pathway in a repressive 
manner, since upon depletion the expression of PI3K kinase proteins increased in both 10A and 
AT1 cells. These findings were found in duplicate (n=2) for RNA expression of PIK3CA and 
PIK3R1 in 10A cells, while the findings for PIK3CA protein expression in AT1 cells were found in 
one biological replicate of shRNA-mediated RUNX1 depletion.  
Discussion & Future Directions 
 Loss-of-function studies are instrumental in advancing our knowledge of how a gene 
exerts regulatory control in the cell. There is evidence that RUNX1 may act as a tumor 
suppressor gene through its action as a transcription factor and master regulator of various 
cellular pathways that are critical to cellular development, survival, growth and proliferation (3, 
4, 45). In this project, two systems were utilized to generate a loss of RUNX1 function in the 
MCF10 BrCa cell series; inducible CRISPRi-dCas9-KRAB and shRNA.  
 Inducible CRISPRi is one of the most well-known genome editing tools in scientific 
research today. The precision, stability and reproducibility of the system make it a premier 
option for use in gene activation or inhibition studies. In this study, inducible CRISPRi 
optimizations and successive trials did not produce a RUNX1 knockdown sufficient for 
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downstream analyses. This, in concert with time constraints, led us to utilize the shRNA system 
for knockdown of RUNX1. However, it may be the case that the inducible CRISPRi system has its 
own limitations depending on the target gene. It was demonstrated here that across multiple 
clonal populations, cells expressed adequate dCas9 protein for multiple days across multiple 
concentrations of doxycycline (Table 4). The expression of dCas9 is a key indicator that the 
inducible system has been acquired by the cell and is a good indication of possible gene 
knockdown. However, a serious concern for inducible CRISPRi that targets RUNX1 is the fact 
that the RUNX1 gene is regulated by two different promoters known as P1 and P2, each of 
which contributes to the overall expression of RUNX1. Additionally, the promoters P1 and P2 
function differently in different cell types. We designed guides for both P1 and P2, three guides 
per promoter for a total of six guides (Table 1). Therefore, in order for the CRISPRi system to be 
effective in generating an appreciable knockdown of at least 80%, gene silencing at both 
promoters P1 and P2 must be achieved. This requirement was likely a limitation for the CRISPRi 
system, as failure of gene knockdown at just one promoter would allow for RUNX1 expression. 
This addresses a major hurdle facing loss-of-function studies, as it can be much more difficult to 
generate a complete silencing of a gene compared to hyper activating or overexpressing a gene.  
 A theoretical limitation of this study may lie within the fact that RUNX1 is a true master 
regulator in the breast epithelial cells. Even as the CRISPRi experiment was optimized, either by 
clonal selection for high dCas9 expression, or by increasing the virus titer, adequate knockdown 
was not consistently achieved. It may be possible that RUNX1 holds a compensatory or reserve 
mechanism to ensure its expression, as it is vital to many processes within the cell including 
signaling pathways, growth and proliferation, cell survival and DNA damage response (4). 
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Similarly, this is plausible since CRISPRi utilizes a deactivated Cas9 in place of Cas9 and does not 
exert nuclease activity on the target gene. It is therefore a matter of steric interference via the 
KRAB repression domain that blocks transcription, not permanent gene excision as seen in the 
classical CRISPR-Cas9 model. This system is therefore developed to create a non-permanent 
loss of RUNX1. For that reason, RUNX1 may be able to exert a compensatory mechanism that 
results in decreased efficiency for dCas9-KRAB binding and transcriptional silencing in the cell.  
 Conversely, perhaps the CRISPRi system is ineffective in targeting RUNX1 at the genomic 
level because doing so activates apoptotic events in the cell. Apoptotic studies were not 
performed in this project, though it may be important to determine if RUNX1 repression at the 
genomic level in BrCa is too catastrophic for the cell, leading to apoptotic events for the 
population of cells that the CRISPRi system was successful. These events would therefore only 
leave behind the population of cells for which RUNX1 expression was not repressed, as seen in 
this project.  
 Other CRISPRi limitations may simply lie within the optimization of the experimental set 
up. We found that increasing the virus titer and raw production of the virus five-fold yielded a 
more efficient knockdown (Figure 14). Further optimization with an even higher virus titer 
could therefore be conducted to generate sufficient knockdown of RUNX1. Additionally, this 
project only utilized a total of six CRISPRi guides (Table 1). Three guides were designed to target 
RUNX1 promoter 1 and three guides were designed to target RUNX1 promoter 2. The online 
CRISPR design tool, Benchling, was utilized in the design of these guides and therefore they 
should contain the necessary parameters for effective knockdown. However, as these guides 
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did not prove very effective, a new set of guides may need to be designed for successful 
knockdown. Due to time constraints for this project, we did not pursue generating new guides. 
 shRNA-mediated depletion of RUNX1 proved to be an effective method of knocking 
down RUNX1 expression at the protein level as well as at the RNA level (Figure 15, Figure 16). 
shRNA targeting RUNX1 was previously performed in our laboratory (3) and was therefore a 
dependable choice for a knockdown system when facing time constraints. At the protein level, 
RUNX1 was knocked down approximately 75% in both the 10A and AT1 cell line. qPCR of two 
replicates in AT1 cells also identified a significant reduction in expression of RUNX1 at the RNA 
level upon shRNA knockdown (Figure 17). These results allowed for further analyses of the 
tumor suppressor role of RUNX1 in BrCa. 
 Quantitative PCR first validated the role of RUNX1 in maintaining the epithelial 
phenotype by preventing EMT as first demonstrated by Hong and colleagues (3). We found that 
in AT1 cells across two replicate samples, a reduction of RUNX1 RNA expression resulted in a 
dramatic decrease of the RNA expression of the epithelial marker E-cadherin, as compared to 
the non-silencing shRNA control (Figure 17). This lends evidence in support of the tumor 
suppressor role of RUNX1 in BrCa, as maintenance of the epithelial phenotype and prevention 
of EMT are essential in preventing cancer progression and aggression.  
 Most notably, we determined that upon depletion of RUNX1, there was a clear increase 
in PIK3CA and PIK3R1 expression at the RNA level in 10A cells (Figure 18). At the protein level, 
an increase in PIK3CA expression was found upon RUNX1 depletion in AT1 cells (Figure 19). 
PIK3CA and PIK3R1 are genes of the phosphatidylinositol-3-kinase (PI3K) pathway that are 
commonly mutated in human cancers (27). PI3K signaling is a critical pathway involved in both 
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normal and malignant cellular processes including cell growth, proliferation and apoptosis 
(Figure 20) (46). Notably, the PIK3CA gene has been found to be mutated in more than one-
third of breast cancers (27). Additionally, one study determined that 9% of the study’s cohort of 
breast cancer patients harbored both PIK3CA and PIK3R1 mutations that resulted in 
hyperactivity of the PI3K pathway and oncogenesis (47).  
 Using an unpublished ChIP-Seq data set that identified where the RUNX1 protein is 
bound throughout the genome (Andrew Fritz), PIK3R1 was identified as a BrCa driver gene that 
RUNX1 binds proximal to the transcription start site (Table 5). Similarly, PIK3CA was identified 
as a BrCa driver gene that RUNX1 binds, though less proximal than the transcription start site of 
PIK3R1. Unpublished RNA-seq data (Andrew Fritz) also determined that upon RUNX1 depletion, 
PIK3CA and PIK3R1 are upregulated in expression (Table 5). RUNX1 regulatory control of PIK3CA 
may therefore occur via distant enhancers or genomic lopping domains, while RUNX1 control of 
the PIK3R1 gene may occur at the transcription start site. It was confirmed that upon RUNX1 
knockdown in BrCa, there is a significant increase in expression of PIK3CA and PIK3R1 compared 
to the non-silencing sample which expressed RUNX1 protein and RNA. Although PIK3CA and 
PIK3R1 are among the most commonly mutated genes in breast cancer, it is the difference 
between the non-silencing vector and the shRNA vector truly targeting RUNX1 that 
demonstrates the regulatory control of RUNX1 on these important PI3K pathway oncogenic 
genes. Since RUNX1 exerts regulatory control with a myriad of genes involved in growth and 
development, the negative regulation of PIK3CA and PIK3R1 may therefore be direct or indirect. 
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The PI3K pathway is vast, exerting control over and interacting with components 
including AKT, mTOR, RAS, VEGF, and EGF, all of which have roles in cell growth, survival, 
proliferation, morphology, apoptosis, migration and adhesion (Figure 20) (9, 48). For these 
reasons, hyperactivation of PIK3CA and PIK3R1 upon loss of RUNX1 may be a critical part of 
cancer progression toward metastasis and invasion, ultimately resulting in poor patient 
prognosis. Moreover, the high frequency of PIK3CA mutations in BrCa has focused on PIK3CA 
inhibition as a novel clinical target and potential drug scheme for BrCa treatment (49). RUNX1 
Figure 20: Schematic of Signaling Through the Phosphatidylinositol-3-Kinase (PI3K)/AKT 
Pathway.  The PI3K/AKT and other interrelated pathways are essential in perceiving the 
effects of external growth signals and associated membrane tyrosine kinases. AKT is 
activated downstream of PI3K and effects a multitude of targets (9). EGFR, epidermal 
growth factor receptor; AMPK, AMP-activated protein kinase; mTOR, mammalian target of 
rapamycin; ERK, extracellular signal regulated kinase; FKHR, forkhead; GDP, guanosine 
diphosphate; IRS, insulin receptor substrate; GSK3, glycogen synthase kinase 3; MAPK, 
mitogen-activated protein kinase; NF-kB, nuclear factor-kB, PIP2, phosphatidylinositol-3,4-
diphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; PKC, protein kinase C.  
Acquired from: Hennessy BT et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005. 
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inhibition may therefore not achieve PI3K inhibition, since RUNX1 may negatively regulate PI3K 
proteins. Rather, RUNX1 activation could work to suppress the hyperactivity of the PI3K 
pathway commonly seen in BrCa.    
Cancer stem cells (CSCs) are another essential area of oncological research today. CSCs 
are a unique subgroup of the cancer cell population able to propagate new tumors while 
displaying the ability to self-renew. These traits contribute to the lethal nature of CSCs, as they 
pose a significant threat when coupled with the canonical hallmarks of cancer (11). CSCs 
are known to evade current cancer treatment options such as chemotherapy and radiation and 
are therefore a crucial facilitator in patient relapses and overall aggression of the cancer. By 
analyzing the downstream gene expression of those genes identified as BrCa drivers in 
response to RUNX1 depletion and their role in CSC formation and/or maintenance, this project 
can further examine the tumor suppressor role of RUNX1 in breast cancer and how RUNX1 may 
work to halt the production of CSCs and the epithelial to mesenchymal transition. With novel 
insight as to how RUNX1 functions in BrCa, we will be able to develop a safer, more targeted, 
and more effective plan of action to eradicate one of the deadliest diseases that exists today.  
In future studies, the role of RUNX1 in the BCSC population can be analyzed via 
CD24/CD44 sorting of cells treated with shRUNX1 and shNon-Silencing. The CSC proportions of 
the culture population can then be found using FACS, as CSCs are characteristically labeled as 
CD24-/CD44+ with regard to cell-surface markers. RNA and protein expression profiles of the 
predicted BrCa driver genes presented here may be carried out on the RUNX1 depleted BCSC 
subpopulation. This, in addition to the qPCR data presented here, will develop a clearer picture 
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of how RUNX1 functions in BrCa progression and aggression. Further studies will also require 
optimization of inducible CRISPRi, a system designed to deplete RUNX1 upon the addition of 
the antibiotic doxycycline through the activation of dCas9. Clonal selection and dCas9 
expression upon dox-induction has been carried out, though more optimization is needed to 
yield a knockout greater than 80% at both promoters of RUNX1. This inducible system will 
provide a real-time snapshot of the effects of RUNX1 depletion, as it can be turned on and off 
with the use of doxycycline. 
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